DMVF3

Rede d1000 is a Brazilian publicly traded company that operates in pharmaceutical retail, with common shares traded on B3 under the ticker DMVF3. The company is the retail arm of Grupo Profarma, which also controls one of the largest distributors of pharmaceutical and personal care products in the country. The trajectory of Rede d1000 began to take shape between 2013 and 2016, through the acquisition and consolidation of traditional drugstore chains such as Drogasmil, Farmalife, Drogarias Tamoio and Drogaria Rosário, all of them with decades of activity in their regional markets. In 2020, the company obtained registration in category A with the CVM and carried out its initial public offering of shares, and its stock began trading on the Brazilian exchange.

The group’s origin is linked to Profarma Distribuidora de Produtos Farmacêuticos S.A., founded in Rio de Janeiro more than six decades ago and listed on B3’s Novo Mercado since 2006. Profarma developed a vertically integrated model combining wholesale distribution and pharmaceutical retail, of which Rede d1000 is the main vehicle in the store segment. Rede d1000’s corporate structure is organized as a holding company that directly controls operating companies, including Nice RJ Participações S.A. and Drogaria Cipriano, which in turn hold stakes in companies such as CSB Drogarias S.A., Drogarias Rosário S.A., Centro-Oeste Farma Distribuidora de Medicamentos and Casa Saba Brasil Holdings. The consolidation of these companies made it possible to create a single retail network, with integrated management, standardized processes and the capture of synergies with the parent company.

Rede d1000’s business model is focused on the retail sale of pharmaceutical and personal care products, constituting a single operating segment. The company does not have its own production processes and operates exclusively in the sale of medicines, hygiene and beauty items, convenience products and a growing portfolio of exclusive brands. As of December 31, 2024, the network comprised 276 physical stores located mainly in the state of Rio de Janeiro, the Federal District and Mato Grosso, in addition to telephone service centers and digital e-commerce platforms and apps for each banner. The company also operates delivery channels, click and collect, and integrates partner marketplace services, which expands the reach of its consumer base.

Rede d1000’s product offering covers three major groups: medicines; personal hygiene, beauty and cosmetics items (HB); and convenience products. In medicines, the company sells branded drugs (reference and similar drugs subject to prescription), generics and OTC/MIPs, aimed at treating acute conditions and those suitable for easy self-diagnosis, such as colds, pain and digestive problems. In hygiene and beauty, the chain sells shampoos, conditioners, hair dyes, treatment creams, children’s products, soaps, deodorants, oral hygiene items, sunscreens, cosmetics, makeup and skincare products. In the convenience category, it offers food items, blood pressure monitors, scales and related products. Since 2014, the company has been developing a portfolio of private label products such as Bem Básico, Bonnevi, Dfresh, GOnutri, Mini Moon, Mise, Nº21, Polimix and Wissen, covering medicines, vitamins, hygiene, beauty and food, a strategy that tends to reinforce margins and assortment differentiation.

Rede d1000’s operations are strongly based on its relationship with the parent company Profarma Distribuição, which accounts for almost all product supply. The network does not operate its own distribution centers, using Profarma’s logistics infrastructure for purchasing, inventory management, and internal and external transportation. This arrangement enables daily deliveries to stores, reduces stockouts, lowers working capital needs and reduces demand for DC investments, in addition to providing greater bargaining power with the pharmaceutical industry due to the consolidated purchasing volume. Distribution to the end consumer takes place through physical stores with long opening hours—most units operate from 7 a.m. to 10 p.m., with some stores open 24 hours—supplemented by brand-specific call centers and proprietary digital channels, which offer home delivery and in-store pickup.

From a geographic standpoint, Rede d1000 focuses its operations on the states of Rio de Janeiro, Mato Grosso, Goiás and the Federal District, where the Drogarias Tamoio, Drogasmil, Farmalife and Rosário banners are located. The company reports a leading position in its main areas of operation, especially in Rio de Janeiro and the Federal District, and ranks among the largest regional chains in number of stores. The market in which it operates is highly fragmented, made up of large national chains, regional chains and independent pharmacies. Among the main competitors mentioned in its regions of operation are Raia Drogasil, Drogaria Pacheco, Drogaria Venâncio, Droga Fuji and Pague Menos. In 2024, the Brazilian pharmaceutical retail sector had more than 90,000 pharmacies and significant revenue, with annual growth above two digits, in line with the essential nature of the health and medicines sector.

Rede d1000’s activities are carried out in a strict regulatory environment, with strong health surveillance. The pharmaceutical sector is regulated at the federal, state and municipal levels, with the main authority being the National Health Surveillance Agency (ANVISA), linked to the Ministry of Health. The operation of drugstores requires compliance with specific laws and decrees, such as Law nº 5,991/1973, Law nº 6,360/1976, Law nº 9,787/1999, Decree nº 8,077/2013 and various ANVISA Board of Directors Resolutions, especially RDC nº 44/2009 and RDC nº 275/2019. Each of the company’s establishments must obtain an Operating Authorization (AFE) from ANVISA, a state or municipal sanitary license, a Certificate of Technical Regularity issued by the Regional Pharmacy Councils, and must comply with requirements regarding the presence of a responsible pharmacist throughout operating hours. The chain states that it substantially complies with these obligations and maintains ongoing processes to renew the necessary licenses.

In terms of environmental, social and governance practices, Rede d1000 has intensified initiatives in recent years. Since 2021, the company has prepared and published annual Sustainability Reports, initially at group level and, more recently, with its own report based on the GRI framework and, in 2024, also on the SASB standard, aligning its strategy with the 2030 Agenda and the UN Sustainable Development Goals. On the social front, a highlight is the long-term partnership with UNICEF, enabled by in-store micro-donations, which has already resulted in cumulative transfers of tens of millions of reais to child health and education projects, in addition to actions carried out jointly with Instituto Profarma in food security, basic hygiene and citizenship. The company also develops governance and integrity programs, such as the DNA Project – Governance in the Network, training sessions on human rights and combating child labor with support from Fundação Abrinq, a more independent whistleblower channel, and internal initiatives focused on diversity and the work environment, recognized by Great Place to Work certification. These actions indicate the growing integration of ESG criteria into corporate management and into the operation of the drugstore network controlled by Rede d1000.

Rede d1000 has no operations abroad and therefore does not record revenue from other countries, maintaining a full focus on the Brazilian market. In 2024, the company reported net revenue of more than R$ 2.1 billion and a positive bottom line, reinforcing the regional relevance of the chain within Brazilian pharmaceutical retail. The combination of traditional banners, operational synergies with the parent company, expansion of digital channels and strengthening of the exclusive brands portfolio shapes the company’s current business model, with its DMVF3 shares remaining listed and traded on B3, reflecting direct exposure to the pharmacy and health, hygiene and beauty products distribution segment in the country.